Lupus Biomarker Discovery, Validation, Approval, and Impact on Clinical Trials

Biomarker discovery and validation.

Currently available biomarkers, such as those used to diagnose myocardial infarction (e.g., cardiac troponins), were identified in the course of targeted physiologic studies. Similarly, basic investigation of diseases has largely been characterized by studies of isolated molecules in cellular systems. Advances in genomics technologies, however, are beginning to permit characterization of global...

Neuroimaging-based biomarker discovery and validation.

Although developing biological markers for chronic pain has been a major goal of the field for decades, such biomarkers have not yet made their way into clinical practice. However, given the potential uses of biomarkers in multiple aspects of prevention and treatment—suchaspain and risk factor assessment, diagnosis, prognosis, treatment selection, drug discovery, and more—efforts to discover ne...

Advances in Clinical Trial Designs for Predictive Biomarker Discovery and Validation

Cancers of the same primary site are in many cases heterogeneous in molecular pathogenesis, clinical course, and treatment responsiveness. Current approaches for treatment development, evaluation, and use result in treatment of many patients with ineffective drugs and lead to the conduct of large clinical trials to identify small, average treatment benefi ts for heterogeneous groups of patients...

Biomarker Discovery, Validation and Clinical Application for Patients Diagnosed with Glioma

Biobank as an Important Tool for Biomarker Discovery and Validation

Biomarker is a measurable indicator, such as protein, genetic alteration, or metabolite that found in tissue, blood, or other body fluids. Identification of biomarkers that specifically associated with the particular medical conditions such as cancer, cardiovascular disease and neurological disorder is useful for early detection, prevent, and therapy of the diseases. Availability of biomarkers ...